BCG vaccination and the risk of COVID 19: A possible correlation.
Virology
; 565: 73-81, 2022 01 02.
Article
in English
| MEDLINE | ID: covidwho-1545481
ABSTRACT
Bacillus Calmette-Guérin (BCG) vaccine is currently used to prevent tuberculosis infection. The vaccine was found to enhance resistance to certain types of infection including positive sense RNA viruses. The current COVID-19 pandemic is caused by positive sense RNA, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A higher mortality rate of COVID-19 patients was reported in countries where BCG vaccination is not routinely administered, when compared to the vaccinated ones. We hypothesized that BCG vaccine may control SARS-CoV2 infection via modulating the monocyte immune response. We analyzed GSE104149 dataset to investigate whether human monocytes of BCG-vaccinated individuals acquire resistance to SARS-CoV-2 infection. Differentially expressed genes obtained from the dataset were used to determine enriched pathways, biological processes, and molecular functions for monocytes post BCG vaccination. Our data show that BCG vaccine promotes a more effective immune response of monocytes against SARS-CoV2, but probably not sufficient to prevent the infection.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
BCG Vaccine
/
Vaccination
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Virology
Year:
2022
Document Type:
Article
Affiliation country:
J.virol.2021.10.003
Similar
MEDLINE
...
LILACS
LIS